Inozyme Pharma Long Term Debt 2020-2024 | INZY

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Inozyme Pharma long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Inozyme Pharma long term debt from 2020 to 2024. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$170.3B
Vertex Pharmaceuticals (VRTX)	$122B
Bristol Myers Squibb (BMY)	$112.5B
Gilead Sciences (GILD)	$111.9B
Regeneron Pharmaceuticals (REGN)	$91.4B
CSL (CSLLY)	$90.8B
GSK (GSK)	$76.6B
Argenex SE (ARGX)	$35.2B
Alnylam Pharmaceuticals (ALNY)	$34.8B
BioNTech SE (BNTX)	$25.9B
Biogen (BIIB)	$25.3B
Illumina (ILMN)	$24.5B
Moderna (MRNA)	$20.6B
BeiGene (BGNE)	$20.2B
Genmab (GMAB)	$15.1B
Incyte (INCY)	$14.6B
Exact Sciences (EXAS)	$13.1B
BioMarin Pharmaceutical (BMRN)	$12.6B
Insmed (INSM)	$12.2B
Bio-Techne Corp (TECH)	$12B
Vaxcyte (PCVX)	$11.9B
Sarepta Therapeutics (SRPT)	$11.7B
QIAGEN (QGEN)	$10B
Exelixis (EXEL)	$9.8B
Bio-Rad Laboratories (BIO.B)	$9.3B
Revolution Medicines (RVMD)	$9.3B
Intra-Cellular Therapies (ITCI)	$9.1B
Roivant Sciences (ROIV)	$8.5B
Legend Biotech (LEGN)	$8B
Repligen (RGEN)	$7.8B